Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors
- 28 October 2004
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 25 (2), 229-244
- https://doi.org/10.1002/med.20020
Abstract
The activity of phosphodiesterases (PDEs) is associated with a wide variety of diseases and an intense effort toward the development of specific PDEs inhibitors has been generated for the last years. They are the enzymes responsible for the hydrolysis of intracellular cyclic adenosine and guanosine monophosphate, and their complexity, as well as their different functional role, makes these enzymes a very attractive therapeutic target. This review is focused on the role of PDEs played on immunomodulatory processes and the advance on the development of specific inhibitors, covering PDEs mainly related to the regulation of autoimmune processes, PDE4 and PDE7. The review also highlights the novel structural classes of PDE4 and PDE7 inhibitors, and the therapeutic potential that combined PDE4/PDE7 inhibitors offer as immunomodulatory agents. © 2004 Wiley Periodicals, Inc. Med Res RevKeywords
This publication has 83 references indexed in Scilit:
- Identification of purine inhibitors of phosphodiesterase 7 (PDE7)Bioorganic & Medicinal Chemistry Letters, 2004
- Synthesis and biological evaluation of neutrophilic inflammation inhibitorsIl Farmaco, 2004
- Crystal Structures of the Catalytic Domain of Phosphodiesterase 4B Complexed with AMP, 8-Br-AMP, and RolipramJournal of Molecular Biology, 2004
- Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects*1Journal of Allergy and Clinical Immunology, 2004
- Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microgliaNeuropharmacology, 2003
- Anti-TNF-α Properties of New 9-Benzyladenine Derivatives with Selective Phosphodiesterase-4- Inhibiting PropertiesBiochemical and Biophysical Research Communications, 2001
- Identification of Human PDE7B, a cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 2000
- Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide PhosphodiesteraseBiochemical and Biophysical Research Communications, 2000
- Suppression of human inflammatory cell function by subtype‐selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4BBritish Journal of Pharmacology, 1999
- Immunosuppressive retroviral peptides: cAMP and cytokine patternsImmunology Today, 1995